Trial · NCT07913282
ARTEMIS: Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) After Mechanical Thrombectomy for Acute Ischemic Stroke
NCT07913282, Phase 1, Not yet recruiting, Royan Stem Cell Technology Company
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. ARTEMIS: Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) After Mechanical Thrombectomy for Acute Ischemic Stroke. Trials, record NCT07913282. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913282
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ARTEMIS: Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) After Mechanical Thrombectomy for Acute Ischemic Stroke
- NCT number
- NCT07913282
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Royan Stem Cell Technology Company
- Conditions
- Acute Ischemic Stroke
- Interventions
- Allogeneic Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs), Standard Stroke Care Including Mechanical Thrombectomy
- First posted
- 2026-11-03
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Serious Adverse Events (SAEs) | During the intervention and 1 hour, 24 hours, 3 days, 7 days, 1 month, 3 months, and 6 months after the intervention | Number of participants experiencing one or more serious adverse events during follow-up, including events resulting in death, life-threatening conditions, prolonged hospitalization, persistent or significant disability, or requiring medical or surgical intervention to prevent such outcomes. Event severity and relationship to the study intervention will be assessed by the clinical team. |
| Primary | Incidence of Adverse Events (AEs) | During the intervention and 1 hour, 24 hours, 3 days, 7 days, 1 month, 3 months, and 6 months after the intervention. | The frequency, type, severity, and relatedness of adverse events associated with intra-arterial infusion of allogeneic umbilical cord-derived mesenchymal stromal cells after mechanical thrombectomy based on Common Terminology Criteria for Adverse Events (CTCAE) version 5. |
| Primary | Feasibility of Intra-Arterial Mesenchymal Stromal Cells Administration | During the intervention (Day 0) | Feasibility will be assessed by the proportion of participants assigned to the intervention group in whom the planned intra-arterial infusion of 20 × 10⁶ allogeneic UC-MSCs is successfully completed according to the study protocol. The number of successful and unsuccessful administrations will be recorded, together with reasons for any failure to initiate or complete the infusion. |
| Secondary | Proportion of Participants with modified Rankin Scale (mRS) 0-2 | Baseline, 24 hours, 3 days, 7 days, 1, 3, and 6 months | Number and percentage of participants with a modified Rankin Scale (mRS) score of 0-2 in each study group, comparing the UC-MSC group with the control group. (mRS ranges from 0 (no symptoms) to 6 (death); higher scores mean greater disability) |
| Secondary | Proportion of Participants with a Reduction in mRS Score Compared with the Initial Pre-Treatment Assessment | Baseline, 24 hours, 3 days, 7 days, 1, 3, and 6 months | Number and percentage of participants achieving a reduction in the modified Rankin Scale (mRS) score, compared between the intervention and control groups. (mRS ranges from 0 (no symptoms) to 6 (death); higher scores mean greater disability.) |
| Secondary | Change in National Institutes of Health Stroke Scale (NIHSS) from baseline | Baseline, 24 hours, 3 days, 7 days, 1, 3, and 6 months | Change from baseline in National Institutes of Health Stroke Scale score. NIHSS ranges from 0 to 42; higher scores mean more severe neurological deficit. |
| Secondary | Change in Serum Brain-Derived Neurotrophic Factor (BDNF) Concentration | Baseline, 3 days, and 6 months after intervention. | Change in serum BDNF concentration from baseline, measured using the protocol-specified laboratory assay and compared between the intervention and control groups. |
| Secondary | Change in Serum Matrix Metalloproteinase-9 (MMP-9) Concentration | Baseline, 3 days, and 6 months after intervention. | Change in serum MMP-9 concentration from baseline, measured using the protocol-specified laboratory assay and compared between the intervention and control groups. |
| Secondary | Change in Serum S100 Concentration | Baseline, 3 days, and 6 months after intervention. | Change in serum S100 concentration from baseline, measured using the protocol-specified laboratory assay and compared between the intervention and control groups. |
| Other | Changes in Cerebral Infarct Volume on CT/MRI | Initial presentation, 24 hours, and 6 months after intervention, | Cerebral infarct core volume will be assessed using brain imaging according to the study protocol. Imaging findings will be evaluated to characterize changes in the extent of cerebral injury during follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913282
GET https://conductscience.org/api/trials/v1/NCT07913282/registered